Introduction
Cerebral venous thrombosis (CVT) is a multi-causal disorder that affects the venous aspect of the neurovascular tree and is related to certain hereditary and acquired predispositions. The incidence, clinical presentation, imaging findings and clinical outcome of CVT are therefore variable and will relate to various risk factors that are predominant in different age groups 1, 2, 3, 4 . CVT can also be a part of the dynamic progression of patients with intracranial dural arteriovenous fistulas as well as being associated with the syndrome of pseudotumor cerebri.
No firm treatment methods for CVT have been established. However, anticoagulation, although not completely scientifically proven, is regarded as a first line treatment 4, 5, 6, 7 . On the contrary, the interventional neuroradiological procedures such as transvenous thrombolysis 8, 9, 10 or mechanical thrombectomy 11, 12 are usually reserved for patients who do not show clinical response to heparin therapy.
The purpose of this article is to discuss the present knowledge of the etiology, clinical presentation, diagnosis and management of this potentially devastating disease from the perspectives of the interventional neuroradiologist.
Clinical Presentation, Imaging and Treatment of Cerebral Venous Thrombosis (CVT) 6 another large group known to be associated with increased risk for venous thrombosis.
The use of oral contraceptives (including third generation) is associated with a four to seven fold increase in the risk for venous thrombosis 15 . The absolute risk remains low with the base-line risk of less then one per 10,000 being increased to three to four per 10,000 person-years during the time when oral contraceptives are used. The risk for CVT increases 20 fold if the females who have an inherited disorder of the hemostatic system such as a mutation in the prothrombin gene use oral contraceptives 16 or 35 fold in women who were heterozygous for factor V Leiden 13 .
Pregnancy and puerperium also increase the risk of venous thrombosis by as much as four fold.
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any known risk factors 3, 7 emphasizing the importance of follow-up investigations.
Clinical Presentation and Natural History
The clinical presentations of patients presenting with CVT (table 2) will depend on the location and extent of the thrombosis (superior sagittal sinus, transverse sinus, straight sinus, T2 weighted axial MR image (B) shows right parietal subacute hematoma and MR venogram (C) does not demonstrate dural sinus occlusion. Because there was no radiologic evidence of CVT, the patient was not given any treatment for 1 week. Follow-up non-enhanced CT (D) shows bilateral intracerebral hemorrhage, dense superior sagittal sinus and subdural fluid collections. MRV (E) demonstrates total occlusion of the superior sagittal sinus. Partial occlusion of distal straight sinus and mid-portion of right transverse sinus are also revealed. Retrograde evaluation of initial MRI (T2 weighted coronal) (F) and MRV source image (G) shows right parietal cortical vein thrombosis without dural sinus involvement. On T2 weighted coronal image (F), thrombosed cortical vein (arrow) shows low signal intensity, so it is difficult to differentiate it from normal vascular signal voids. However, on MRV source image (G), it turns to high signal intensity (arrow) suggesting acute thrombosed cortical vein.
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This risk is much greater shortly after delivery than during pregnancy, the incidence of thrombosis is 25 fold higher in the postpartum period than during pregnancy 1 .
The chance in a female below the age of 40 who presents with a cerebral ischemic event for it to be caused by venous thrombosis is two fold higher than for it to be arterial in origin. However, about 20% of the cases do not show cortical versus deep venous system). The clinical impact of the venous thrombosis varies according to the patient's venous anatomical disposition such as collateral pathways. Frequently, the symptoms and signs of CVT are nonspecific such as headaches and vomiting lasting hours or days.
These most likely reflect global increased venous pressure related to early dural sinus thrombosis. Such presentation in association with new onset of seizures, papilledema, decreased mentation and focal neurological deficit should raise a strong suspicion of venous occlusive disease affecting the cortical venous system. Seizures may be focal or generalized but they occur in about half of the patients.
The progression of CVT is slow and stepwise. Clinically, it is expressed as accumulative symptoms and signs sometimes extending over days or even weeks. So, crescendo type progression of clinical presentations from non-specific symptoms to seizure or focal neurological deficit over a few days is almost characteristic of the diagnosis and should lead to rapid management. Simultaneous venous occlusive disease involving other body parts is not rare and pulmonary embolism has been demonstrated in up to 11% of patients with dural sinus thrombosis 17 .
Historically, CVT was believed to be a disease with a poor prognosis. According to the placebo arms of the two prospective data 5, 18 , about 41% of patients showed poor outcome defined as a death or Barthel index <15. However, recent advances in imaging and increased clinical awareness resulted in earlier medical therapy and showed the mortality rates to be less than 10% 3, 19 . Despite its relatively more benign clinical course than previously assumed, a small subgroup reveals rapid clinical progression leading to status epilepticus, progressive loss of consciousness and a comatose state, which without treatment is associated with 69% mortality 18 .
Imaging
Clinical suspicion of the CVT will greatly facilitate the radiological interpretation of subtle abnormalities that may be shown in the early stage of the disease.
Vice versa, the radiological findings interpreted with awareness of this clinical condition may result in an early diagnosis despite nonspecific clinical symptoms.
Computerized tomography (CT), because of its easy access, is probably used in most instances as the first imaging modality. It may 20 . Unilateral low attenuated lesion involving the temporal lobe can be shown in transverse sinus thrombosis. The low attenuations on plain CT may reflect vasogenic edema resulting from venous outflow disturbances 21 . If the venous cerebral ischemia is prolonged, hemorrhagic conversion occurs and it becomes readily visible on plain CT. Recently developed thin-section helical CT venography is also a very useful tool to diagnose cerebral venous thrombosis 22 .
Magnetic resonance imaging (MRI) has proven to be the modality of choice and has surpassed cerebral angiography in its ability to demonstrate dural sinus thrombosis and venous ischemia 23 .
Conventional MRI sequences can demonstrate clot within the dural sinuses with different signal characteristics depending on the age of the clot, various degrees of brain edema and/or intracerebral hemorrhage. Additionally, MRI can reveal cortical venous thrombosis without dural sinus occlusion (figure 1). In our experience, even in the presence of significant and extensive changes on CT and MRI, these radiologic changes may resolve after active medical and endovascular management and result in good clinical outcome. Recently, gadolinium enhanced MR angiography showed its potential to depict the components of intracranial arteriovenous shunts especially intracranial arteriovenous malformation 24 and MR venography can demonstrate the normal intracranial venous system 25 .
These techniques may obviate the need for conventional diagnostic angiography. However, certain limitations of MRI have to be kept in mind as they need correct interpretations. For example, the presence of hyperacute cerebral hemorrhage and the demonstration of thrombosis in cortical veins associated with a patent adjacent dural sinus are still somewhat difficult to discern on MRI. Careful analysis of the MRI (including the source images) is required to decode various signal characteristics of the clots within the venous channels, the developing venous congestion and infarction. Although the experiences in cerebral venous ischemia with diffusion and perfusion weighted imaging (DWI and PWI) are still limited, early results have shown the potential to predict whether brain tissue is still viable and active intervention is recommended 26 .
Cerebral angiography is nowadays rarely used for the diagnostic purpose of CVT. However, angiography can provide very important additional information on intracranial circulations. It can demonstrate individual host response to the presence of venous thrombosis. For instance, it may reveal alteration of the venous phase of brain circulation including so called pseudo-phlebitic patterns 27 suggesting venous congestions and can show alternate (collateral) venous pathways being used if it was developed. These physiological responses of venous thrombosis may explain and provide some clues to the individual differences (clinical presentation and outcome) of CVT patients. Moreover, the information shown at angiography cannot be demonstrated on CT or MRI. 
Treatment
Proper management of CVT patients is mainly dependent on our ability to make a clinical suspicion and radiological confirmation of this diagnosis, which continues to be our biggest challenge. Timely diagnosis is critical for effective treatment.
Once the diagnosis is made, medical therapy that includes systemic anticoagulation, hydration and anticonvulsant therapy is started. For 15 years, anticoagulation therapy has been used routinely for the treatment of intracranial venous thrombosis.
To investigate the scientific evidence of heparin's benefit for CVT treatment, two randomized trials and one meta-analysis have been conducted. The first trial, a randomized, blinded placebo-controlled study in 20 aseptic dural sinus thrombosis patients, concluded that anticoagulation with dose-adjusted intravenous heparin was an effective treatment and associated intracranial hemorrhage was not a contraindication for its use 18 .
The trial was stopped after 20 patients because of the dramatic difference in outcome between the heparin and placebo group. A statistically significant beneficial effect of heparin treatment was seen after three days of therapy and confirmed at every subsequent examination up to three months after the start of treatment. However, this trial was challenged 28 with respect to the use of the non-validated outcome assessment method, the delay in treatment starting point and failure to clarify the duration of heparin treatment and the utilization of warfarin.
A second randomized trial 5 investigating the role of low molecular heparin in the management of cerebral venous thrombosis demonstrated the safety of anticoagulant therapy, even in the presence of hemorrhagic lesions on CT. Patients in this trial were treated at an earlier stage of the disease and their clinical conditions were less severe as compared to the first trial. However, a statistically significant improvement in clinical outcome was not demonstrated. A meta-analysis 5 of the above two trials showed a mortality reduction of 14.3% with heparin treatment and 15.5% risk reduction for the combined outcome including "death or dependence".
Again, although this result showed an improvement in the clinical outcome of heparin treatment, no statistically significant improvement was demonstrated.
Therefore, we still do not have a proven statistically significant clinical improvement of heparin therapy for CVT over placebo. Nevertheless, the unpredictable clinical outcome, known safety of heparin therapy and favorable trends of clinical results shown in previous trials, are assumed to reinforce the use of heparin as a first line treatment for CVT 7 .
However, the effect of heparin that can usually be seen within the first day of treatment may be too slow to help a special subgroup of CVT patients. Patients with rapidly progressing thrombosis that involves large parts of the cerebral venous system, with diffuse brain swelling and multiple hemorrhages are considered to have a poor prognosis. Therefore, it is this subgroup that should be considered for thrombolytic therapy as it represents the only possible treatment method, which may prevent catastrophic outcome. It has been our practice to wait for the impact of anticoagulation therapy for at least 24 hours. But if clinical worsening continues during that time period, then we consider thrombolytic therapy (figure 2).
Vines and Davis 29 were the first to propose thrombolytic therapy (urokinase) in the management of CVT, followed by Di Rocco et Al 30 who used intravenous Urokinase in combination with heparin treatment. Treatment with local urokinase infusion into the dural sinus was first performed in 1988 31 . Subsequently several reports demonstrated the feasibility and use of thrombolytic agents infusion into the thrombosed dural sinus via direct percutaneous or retrograde transvenous approach 9, 11, 32, 33 . With improved catheter technology, it also became possible to access and infuse thrombolytic agents into the deep venous system via the straight sinus 10, 34, 35 . The potential benefit of local administration of thrombolytic therapy is that it can avoid the systemic hemorrhagic effects caused by high dose intravenous anticoagulation therapy.
The dose, method and type of thrombolytic therapy have changed over the past decade from prolonged infusions of low dose Urokinase therapy to more rapid pulse spray techniques using tissue type plasminogen activator (tPA). The duration and dose has ranged from 2 to 244 hours to infuse 0.5 to 20 million Units of Urokinase and from 2 to 43 hours to admin-ister 50 to 300 mg of tPA 8, 32, 33, 35, 36 . Local injection of tPA in combination with heparin appears to carry a higher risk for worsening the intracerebral hemorrhage than heparin alone in patients with pretreatment hemorrhagic infarction. Additionally, there are still some technical points which need to be clarified such as the dose of thrombolytic agents, duration of treatment and concomitant use of anticoagulant 4 .
However, at least in the CVT patients without obvious pretreatment hemorrhage, endovascular treatment showed safety, rapid flow restoration and improvement of clinical outcome 6 . While endovascular thrombolysis is being explored, the important fact to keep in mind is that we do not have a clearly defined end point of this therapy. Although most interventional neuroradiologists prefer total absence of clot in the dural sinuses at the end of the procedure, this may in fact not be necessary. In our experience, the reestablishment of antegrade flow is often sufficient to facilitate clinical improvement. After reestablishment of antegrade flow, continued anticoagulation will prevent propagation of clot and in time the lumen of the sinus will become fully reestablished.
Other techniques to re-open the venous channels more rapidly have been explored in combination with thrombolytic therapy. These include mechanical disruption using guidewires, rheolytic thrombectomy catheters, balloon thrombectomy with fibrinolysis, transluminal balloon angioplasty with or without stenting and surgical thrombectomy 36, 37, 38, 39, 40 . The role of endovascular reopening of the dural sinuses using transvenous thrombolytic therapy as well as retrograde transvenous angioplasty and stent placement is currently being explored for those patients demonstrating a relentless, progressive neurological deterioration and has shown promising results in selected cases 41, 42 .
Conclusions
CVT has extremely variable clinical presentations, imaging findings and unpredictable clinical outcome. While there is still no scientifically proven treatment, heparin treatment appears to be safe and has shown a trend to result in clinical improvement. Endovascular treatments including transvenous thrombolysis combined with intravenous heparin therapy, mechanical thrombectomy and angioplasty with or without stenting are promising, but their exact indications will need to be further established and validated.
